‘Swift’ Vascepa Victory Puts Hikma And Reddy’s In Pole Position
But Analyst Calls Generic Threat ‘Overstated’
Executive Summary
Hikma and Dr Reddy’s Laboratories are weighing launches of their generics to Amarin’s Vascepa after the US Court of Appeals for the Federal Circuit upheld a favorable lower court ruling. The originator said it would take its appeal to the next level and continued to raise doubts over supply capacity.
You may also be interested in...
Hikma Is Keeping On Top Of COVID ‘Rollercoaster’
Careful supply-chain planning and an agile, flexible approach to manufacturing have been key in helping Hikma to stay on top of the “rollercoaster ride” provided by the COVID-19 pandemic in 2020 so far, according to CEO Siggi Olafsson.
Supply Chain Constraints ‘Will Limit Vascepa Threat’
Supply is the million-dollar question for Vascepa ANDA sponsors, with Dr Reddy’s and Hikma receiving a further green light to introduce their generics into the US market.
Amarin Makes Vascepa Generics Prediction And Questions Supply
Amarin – and the industry at large – was stunned in March this year when Hikma and Dr Reddy’s walked away from court with an invalidity ruling against six Vascepa patents in the US. The originator’s CEO gave an impassioned update on the current state of play, including the potential for generics to launch ahead of a Federal Circuit ruling later this year or early in 2021.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: